Best Practice & Research Clinical Rheumatology
Volume 23, Issue 5 , Pages 699-708 , October 2009

What's new in paediatric SLE?

  • Emily von Scheven (Professor of Pediatrics)

      Affiliations

    • Pediatric Rheumatology, 533 Parnassus Avenue, Box 0107, University of California, San Francisco, CA 94143, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 415 476 2491; Fax: +1 415 502 7540.
    • ,
  • Aysin Bakkaloglu (Professor of Pediatric Nephrology)

      Affiliations

    • Hacettepe University, Faculty of Medicine, Ankara, Turkey

References 

  1. Petty R, Laxer R. Systemic lupus erythematosus. In:  Cassidy J,  Petty R editor. Textbook of pediatric rheumatology. 5th edn.. Philadelphia: WB Saunders, Co.; 2005;p. 342–385
  2. Tucker LB, Menon S, Schaller JG, Isenberg DA. Adult- and childhood-onset systemic lupus erythematosus: a comparison of onset, clinical features, serology, and outcome. Br J Rheumatol. 1995;34(9):866–872
  3. Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006;54(8):2550–2557
  4. Ravelli A, Ruperto N, Martini A. Outcome in juvenile onset systemic lupus erythematosus. Curr Opin Rheumatol. 2005;17(5):568–573
  5. Bakkaloglu A. Lupus nephropathy in children. Nephrol Dial Transplant. 2001;16(Suppl. 6):126–128
  6. Appel G, D'aqati V. Renal involvement in multisystem diseases. Part I: lupus nephritis. In:  Massrey S,  Glassock R editor. Textbook of nephrology. 4th edn.. Philadelphia: Lippincott Williams & Wilkins; 2001;p. 777–781
  7. Mavragani CP, Moutsopoulos HM. Lupus nephritis: current issues. Ann Rheum Dis. 2003;62(9):795–798
  8. Bertsias GK, Nakou M, Choulaki C, et al. Genetic, immunologic, and immunohistochemical analysis of the programmed death 1/programmed death ligand 1 pathway in human systemic lupus erythematosus. Arthritis Rheum. 2009;60(1):207–218
  9. Cameron JS. Lupus and lupus nephritis in children. Adv Nephrol Necker Hosp. 1993;22:59–119
  10. Gordon C, Jayne D, Pusey C, et al. European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus. 2009;18(3):257–263
  11. Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004;15(2):241–250
  12. Niaudet P. Treatment of lupus nephritis in children. Pediatr Nephrol. 2000;14(2):158–166
  13. Marks S, Tullus K. Lupus nephritis. In:  Geary D,  Schaefer F editor. Comprehensive pediatric nephrology. 1st edn.. Philadelphia: Elsevier; 2008;p. 329–342
  14. Marks SD, Sebire NJ, Pilkington C, Tullus K. Clinicopathological correlations of paediatric lupus nephritis. Pediatr Nephrol. 2007;22(1):77–83
  15. Austin HA, Boumpas DT, Vaughan EM, Balow JE. High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant. 1995;10(9):1620–1628
  16. Faurschou M, Starklint H, Halberg P, Jacobsen S. Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure. J Rheumatol. 2006;33(8):1563–1569
  17. Gamba G, Quintanilla L, del Bosque MD, Chew-Wong A, Correa-Rotter R. Clinical course and prognostic factors in lupus nephropathy, Rev Invest Clin. 2000;52(4):397–405
  18. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002;46(8):2121–2131
  19. Bansal VK, Beto JA. Treatment of lupus nephritis: a meta-analysis of clinical trials. Am J Kidney Dis. 1997;29(2):193–199
  20. Sinclair A, Appel G, Dooley MA, et al. Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS). Lupus. 2007;16(12):972–980
  21. Lewis EJ, Hunsicker LG, Lan SP, Rohde RD, Lachin JM. A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N Engl J Med. 1992;326(21):1373–1379
  22. Wright EC, Tullus K, Dillon MJ. Retrospective study of plasma exchange in children with systemic lupus erythematosus. Pediatr Nephrol. 2004;19(10):1108–1114
  23. Marks SD, Patey S, Brogan PA, et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum. 2005;52(10):3168–3174
  24. Masood S, Jayne D, Karim Y. Beyond immunosuppression - challenges in the clinical management of lupus nephritis. Lupus. 2009;18(2):106–115
  25. Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004;350(10):971–980
  26. Siso A, Ramos-Casals M, Bove A, et al. Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. Lupus. 2008;17(4):281–288
  27. Bjornadal L, Yin L, Granath F, Klareskog L, Ekbom A. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964–95. J Rheumatol. 2004;31(4):713–719
  28. Fischer LM, Schlienger RG, Matter C, Jick H, Meier CR. Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am J Cardiol. 2004;93(2):198–200
  29. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. 1997;145(5):408–415
  30. Hersh AO, von Scheven E, Yazdany J, et al. Differences in long-term disease activity and treatment of adult patients with childhood- and adult-onset systemic lupus erythematosus. Arthritis Rheum. 2009;61(1):13–20
  31. Berenson GS, Wattigney WA, Tracy RE, et al. Atherosclerosis of the aorta and coronary arteries and cardiovascular risk factors in persons aged 6 to 30 years and studied at necropsy (The Bogalusa Heart Study). Am J Cardiol. 1992;70(9):851–858
  32. Falaschi F, Ravelli A, Martignoni A, et al. Nephrotic-range proteinuria, the major risk factor for early atherosclerosis in juvenile-onset systemic lupus erythematosus. Arthritis Rheum. 2000;43(6):1405–1409
  33. Ilowite NT, Samuel P, Ginzler E, Jacobson MS. Dyslipoproteinemia in pediatric systemic lupus erythematosus. Arthritis Rheum. 1988;31(7):859–863
  34. Posadas-Romero C, Torres-Tamayo M, Zamora-Gonzalez J, et al. High insulin levels and increased low-density lipoprotein oxidizability in pediatric patients with systemic lupus erythematosus. Arthritis Rheum. 2004;50(1):160–165
  35. Sarkissian T, Beyenne J, Feldman B, Adeli K, Silverman E. The complex nature of the interaction between disease activity and therapy on the lipid profile in patients with pediatric systemic lupus erythematosus. Arthritis Rheum. 2006;54(4):1283–1290
  36. Soep JB, Mietus-Snyder M, Malloy MJ, Witztum JL, von Scheven E. Assessment of atherosclerotic risk factors and endothelial function in children and young adults with pediatric-onset systemic lupus erythematosus. Arthritis Rheum. 2004;51(3):451–457
  37. Svenungsson E, Gunnarsson I, Fei GZ, et al. Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum. 2003;48(9):2533–2540
  38. Hayata AL, Borba EF, Bonfa E, Kochen JA, Goldenstein-Schainberg C. The frequency of high/moderate lipoprotein risk factor for coronary artery disease is significant in juvenile-onset systemic lupus erythematosus. Lupus. 2005;14(8):613–617
  39. Ilowite NT, Copperman N, Leicht T, Kwong T, Jacobson MS. Effects of dietary modification and fish oil supplementation on dyslipoproteinemia in pediatric systemic lupus erythematosus. J Rheumatol. 1995;22(7):1347–1351
  40. Camejo G, Olofsson SO, Lopez F, Carlsson P, Bondjers G. Identification of Apo B-100 segments mediating the interaction of low density lipoproteins with arterial proteoglycans. Arteriosclerosis. 1988;8(4):368–377
  41. McMahon M, Hahn BH. Atherosclerosis and systemic lupus erythematosus: mechanistic basis of the association. Curr Opin Immunol. 2007;19(6):633–639
  42. Navab M, Berliner JA, Watson AD, et al. The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol. 1996;16(7):831–842
  43. Fernandes JL, Mamoni RL, Orford JL, et al. Increased Th1 activity in patients with coronary artery disease. Cytokines. 2004;26(3):131–137
  44. Thompson T, Sutton-Tyrrell K, Wildman RP, et al. Progression of carotid intima-media thickness and plaque in women with systemic lupus erythematosus. Arthritis Rheum. 2008;58(3):835–842
  45. Houghton KM, Tucker LB, Potts JE, McKenzie DC. Fitness, fatigue, disease activity, and quality of life in pediatric lupus. Arthritis Rheum. 2008;59(4):537–545
  46. Schanberg LE, Sandborg C, Barnhart HX, et al. Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort. Arthritis Rheum. 2009;60(5):1496–1507

PII: S1521-6942(09)00078-3

doi: 10.1016/j.berh.2009.07.008

Best Practice & Research Clinical Rheumatology
Volume 23, Issue 5 , Pages 699-708 , October 2009

Article Tools

* Image Usage & Resolution